Cyclic di-GMP disodium (Synonyms: c-di-GMP, Cyclic diguanylate, 3',5'-Cyclic diguanylic acid) |
Catalog No.GC19526
One-Click Copy Product Info
|
Cyclic di-GMP disodium is a cyclic dinucleotide signaling molecule synthesized by bacteria and is a STING agonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2222132-40-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cyclic di-GMP disodium is a cyclic dinucleotide signaling molecule synthesized by bacteria and is a STING agonist [1]. Cyclic di-GMP disodium induces increased CD4 receptor expression and causes cell cycle arrest [2-3]. Cyclic di-GMP disodium is often used in cancer research [4].
In Escherichia coli, Cyclic di-GMP disodium (7.5μM; 18-24h) rescues rLCN2-mediated inhibition of Escherichia coli growth [5]. In H508 cells, Cyclic di-GMP disodium (2-400μM; 72h) inhibits basal and growth factor-induced proliferation of human colon cancer [1]. In CD4+ T cells, Cyclic di-GMP disodium (3μg/mL, 10μg/mL; 24h) treatment of anti-CD3/CD28 stimulated wild-type T cells resulted in significant inhibition of proliferation and upregulation of CD80 expression [6]. In myeloid-derived suppressor cells (MDSCs), low doses of Cyclic di-GMP disodium (0.2μM; 24h) significantly increased IL12 production [7].
In mouse mastitis model, prophylactic pretreatment of mice with Cyclic di-GMP disodium (1mg/kg, 4.1mg/kg; sc; injected every 6 hours, twice in total) inhibits infection [8]. In a mouse bacterial pneumonia model, pretreatment of mice with Cyclic di-GMP disodium (2.5mg/kg; sc; injected every 12 hours, twice in total) induced a significant protective immune response against challenge with a virulent strain of Klebsiella pneumoniae [9]. In pertussis mouse model, injection of Cyclic di-GMP disodium (2.5mg/kg; nasal; single administration) can induce protective immune responses against Bordetella pertussis bacterial challenge [10].
References:
[1]. Karaolis DK, Cheng K, Lipsky M, et al. 3′, 5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochemical and biophysical research communications. 2005 Apr 1; 329(1): 40-45.
[2]. Wang Z, Celis E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunology, Immunotherapy. 2015 Aug; 64: 1057-1066.
[3]. JSteinberger O, Lapidot Z, Ben-Ishai Z, et al. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3′, 5′-cyclic diguanylic acid. FEBS letters. 1999 Feb 5; 444(1): 125-129.
[4]. Jenal U, Reinders A, Lori C. Cyclic di-GMP: second messenger extraordinaire. Nature Reviews Microbiology. 2017 May; 15(5): 271-284.
[5]. Li W, Cui T, Hu L, et al. Cyclic diguanylate monophosphate directly binds to human siderocalin and inhibits its antibacterial activity. Nature Communications. 2015 Sep 22; 6(1): 8330.
[6]. Concepcion AR, Wagner LE, Zhu J, et al. The volume-regulated anion channel LRRC8C suppresses T cell function by regulating cyclic dinucleotide transport and STING–p53 signaling. Nature immunology. 2022 Feb; 23(2): 287-302.
[7]. Chandra D, Quispe-Tintaya W, Jahangir A, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer immunology research. 2014 Sep 1; 2(9): 901-910.
[8]. Karaolis DK, Means TK, Yang D, et al. Bacterial c-di-GMP is an immunostimulatory molecule. The Journal of Immunology. 2007 Feb 15; 178(4): 2171-2181.
[9]. Karaolis DK, Newstead MW, Zeng X, et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infection and immunity. 2007 Oct; 75(10): 4942-4950.
[10]. Elahi S, Van Kessel J, Kiros TG, et al. c-di-GMP enhances protective innate immunity in a murine model of pertussis. PloS one. 2014 Oct 15; 9(10): e109778.
| Antibacterial experiment [1]: | |
|
Bacterial |
Escherichia coli |
|
Preparation Method |
To evaluate whether Cyclic di-GMP disodium could alleviate the inhibitory effect of rLCN2 on bacterial growth, Escherichia coli (E. coli) was cultured in standard 7H9-OADC and M9 medium, respectively, and treated with 0.15μM rLCN2 at 37℃, and Cyclic di-GMP disodium (7.5μM) was added. The colony forming units (CFU) were measured at different time points (18-24h). |
|
Reaction Conditions |
7.5μM; 18-24h |
|
Applications |
Cyclic di-GMP disodium rescues rLCN2-mediated inhibition of E. coli growth. |
| Animal experiment [2]: | |
|
Animal models |
Mouse mastitis model |
|
Preparation Method |
12 and 6h before bacterial inoculation, saline or 50 or 200nmol of Cyclic di-GMP disodium was administered into the fourth pair of abdominal mammary glands of lactating CD-1 mice. Administration of 50 and 200nmol of Cyclic di-GMP disodium corresponded to a dose of 1.0 and 4.1mg of compound per kg of body weight, respectively, considering an average weight of 35g for a mouse. For inoculation, 100 CFU of S. aureus Newbould 305 (ATCC 29740) were injected into each gland and the colonization was allowed for 10h. Raw bacterial CFU counts obtained after plating serial logarithmic dilutions of mammary gland homogenates were transformed in base 10 logarithm values. |
|
Dosage form |
1mg/kg, 4.1mg/kg; sc; injected every 6 hours, twice in total |
|
Applications |
Prophylactic pretreatment of mice with Cyclic di-GMP disodium inhibits infection in vivo. |
|
References: |
|
| Cas No. | 2222132-40-1 | SDF | |
| Synonyms | c-di-GMP, Cyclic diguanylate, 3',5'-Cyclic diguanylic acid | ||
| Chemical Name | guanylyl-(3'→5')-3'-guanylic acid, cyclic nucleotide, disodium salt | ||
| Canonical SMILES | O=C1NC(N)=NC2=C1N=CN2[C@@H]([C@@H]3O)O[C@@]([H])([C@]3(OP([O-])(OC[C@]([H])([C@]4(O5)[H])O[C@H]([C@@H]4O)N6C(N=C(N7)N)=C(N=C6)C7=O)=O)[H])COP5([O-])=O.[Na+].[Na+] | ||
| Formula | C20H22N10O14P2Na2 | M.Wt | 734.4 |
| Solubility | 1mg/mL in water | Storage | Store at -80°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3617 mL | 6.8083 mL | 13.6166 mL |
| 5 mM | 272.3 μL | 1.3617 mL | 2.7233 mL |
| 10 mM | 136.2 μL | 680.8 μL | 1.3617 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)